Brief: Viralytics
Corporate news snapshot for Viralytics
Viralytics (VLA) has had success with its Phase I late stage melanoma trial of Cavatak. The primary safety objective of this trial was to assess the safety and tolerability of two doses of Cavatak when injected directly to a single tumour.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles